// App-Quantinova.ai

TPS2656 : Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

Researchers

Presenter

  • Keun Wook Lee

Principal Investigators

  • Young-Hyuck Im

  • Keun Seok Lee

  • Jae Yong Cho

  • Do-Youn Oh

  • Hyun Cheol Cheol Chung

  • Yee Chao

  • Li-Yuan Bai

  • Chia Jui Yen

  • In-Ho Kim

  • Sang Cheul Oh

  • Chia-Chi Lin

  • Jin Wang

  • Xin Wang

  • Huiyan Li

  • Yen-Yang Chen

  • Yoon-Koo Kang

Medical Centers

  • Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • National Cancer Center, Goyang-si, Korea

  • Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • Department of Oncology, Taipei Veterans General Hospital, Taipei City, Taiwan, China Medical University Hospital, China Medical University, Taichung, Taiwan, National Cheng Kung University Hospital, Tainan City, Taiwan, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea

  • Korea University Guro Hospital, Seoul, Korea

  • National Taiwan University Hospital, Taipei, Taiwan, BeiGene (Shanghai) Co., Ltd., Shanghai, China

  • Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Asan Medical Centre, University of Uslan College of Medicine, Seoul, South Korea

Locations

  • China

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Tislelizumab

  • Capecitabine

  • Oxaliplatin

  • Docetaxel

  • Capecitabine + Oxaliplatin

Outcome

  • N/A

Study Design

  • Open Label

  • Cohort

Phase

  • I

Study Id's

  • NCT02892123

  • NCT04276493

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved